Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients
Peng Zhao, Clara Effenberger, Saki Matsumoto, Takafumi Morisaki, Yu Ishii, Masayo Umebayashi, Hiroto Tanaka, Norihiro Koya, Shinichiro Nakagawa, Kenta Tsujimura, Yusuke Nakamura, Takashi Morisaki, Kazuma Kiyotani · 2026
Read Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients by Peng Zhao, Clara Effenberger, Saki Matsumoto, Takafumi Morisaki, Yu Ishii, Masayo Umebayashi, Hiroto Tanaka, Norihiro Koya, Shinichiro Nakagawa, Kenta Tsujimura, Yusuke Nakamura, Takashi Morisaki, Kazuma Kiyotani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13286890.txt.
Description
Peng Zhao and colleagues ask what makes a cancer vaccine peptide stir the immune system. Their 2026 study covers 352 patients who got vaccines built from their own tumors. The team checked more than two thousand short peptides with a lab test. Few chosen peptides work, so the rules for picking them need work.
Peptides that worked did not share a set place or pattern in their code. They did tend to repel water more than the rest. Scores that rate how well a peptide binds and stays on immune display proteins ran higher for them. A mix of body traits and scores beat each tool on its own. The results should help vaccine makers rank their picks.
Catalog record
| CREATOR | Peng Zhao, Clara Effenberger, Saki Matsumoto, Takafumi Morisaki, Yu Ishii, Masayo Umebayashi, Hiroto Tanaka, Norihiro Koya, Shinichiro Nakagawa, Kenta Tsujimura, Yusuke Nakamura, Takashi Morisaki, Kazuma Kiyotani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |